From patients and care providers to pharmaceutical companies and public procurers, sustainable, innovative healthcare is clearly a goal for all. At the same time, only 34% believe they will have access to the best cancer medicines if treated in Norwegian public hospitals, according to Kantar TNS.
R&D investment vs. cost containment is at the core of many of today’s healthcare debates – in Norway and abroad. How can we best address this ongoing struggle?
Please join members of parliament, healthcare providers, international company directors and, most importantly, patients (potentially all of us!) as we delve deeper than the tabloid headlines that often frame dialogue on sustainable, innovative healthcare.
Medvirkende
Jónas Einarsson, CEO, Norwegian Radium Hospital Research Foundation
Pierre Claude Fumoleau, General Manager, AbbVie Norway
Kristin Ørmen Johnsen, Standing Committee on Health & Care Services - Høyre, Stortinget
Ole Alexander Opdalshei, Assistant General Secretary, Norwegian Cancer Society